Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4SCAR-T Therapy in CD19-Negative B-ALL
NCT04430530Phase 2Terminated
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Jun 2026
- Primary completion
- Jul 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 4SCAR-T in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Shenzhen Geno-Immune Medical Institute. Primary endpoint: Safety of fourth generation anti-CD22/CD123/CD38/CD10/CD20 CAR-T cells at 24 weeks. Started Jun 2026; status: terminated.
02
Drugs
4SCAR-T
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT04430530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04430530.